Emgality (Galcanezumab) for Migraine Prevention
Written by Medicover Team and Medically Reviewed by Dr Vikram Kishore Reddy P, Neurology
Galcanezumab tablets are a prescription drug used primarily to prevent migraines and manage cluster headaches. It belongs to a class of medications known as monoclonal antibodies that target specific proteins involved in migraine attacks. Reducing the frequency and severity of migraines helps improve the quality of life for patients suffering from chronic headaches. Emgality is typically administered as a monthly injection and is known for its long-lasting effect. Patients report fewer migraine days and improved daily function with consistent use.
Emgality (Galcanezumab) Tablet is a calcitonin gene-related peptide (CGRP) antagonist. It is designed to block CGRP, a molecule believed to play a major role in causing migraines. Emgality is available as an injectable medication, not in tablet form, despite some common references to "Emgality Tablets." It is FDA-approved for preventing episodic and chronic migraines in adults. This targeted therapy offers an advanced approach compared to traditional preventive treatments and is generally well-tolerated with minimal interference in daily routines.
Emgality tablets are mainly used for migraine prevention. It helps reduce the number of migraine days per month and provides relief to those suffering from frequent or debilitating headaches. The Emgality also extend to treating episodic cluster headaches, a rare but severe condition. Benefits include fewer attacks, reduced need for painkillers, and less time off work or daily activities. Many patients experience improvements within the first month of treatment, especially when following the recommended Emgality dosage instructions from their doctor.
Galcanezumab is a preventive migraine treatment designed to help reduce the number of attacks and improve quality of life. It works by targeting CGRP (calcitonin gene-related peptide), a molecule believed to play a key role in migraine onset. This medicine is not used to stop a migraine once it'starts, but rather to prevent future occurrences. It is especially helpful for patients who suffer from frequent or debilitating migraine episodes.
Key Conditions Treated:
Always consult a healthcare provider before starting Emgality to ensure it's the right preventive therapy for your condition.
Although primarily used for migraines and cluster headaches, Emgality (Galcanezumab) medicine may sometimes be explored for off-label uses, such as other forms of chronic neuralgic pain. These secondary uses are not widely approved and must be considered carefully by a healthcare professional. Since it targets CGRP pathways explicitly, researchers are investigating its role in other pain-related conditions. However, self-treatment for anything outside its approved indications is strongly discouraged without professional guidance.
Galcanezumab medicine works by targeting the calcitonin gene-related peptide (CGRP), which is known to trigger migraine pain. It blocks CGRP's ability to bind to its receptor, thereby preventing the cascade of events that cause blood vessel dilation and inflammation in the brain. Unlike general painkillers, this treatment focuses on the root biological mechanism. It does not act on the nervous system or hormone levels directly but intervenes at a specific molecular level, making it a highly targeted and modern migraine therapy.
The Emgality dosage typically includes:
Always follow your doctor's prescribed Emgality dosage, as individual needs may vary. Injections should be administered subcutaneously, often in the thigh, abdomen, or upper arm, and patients may be trained for self-administration at home.
If you miss a scheduled dose of Emgality (Galcanezumab) medicine, take it as soon as you remember. Continue your monthly injections based on the new date. It's important to maintain a consistent interval between doses to ensure optimal migraine prevention. Do not double up or inject sooner than advised. Set reminders to stay on track with your Emgality dosage schedule and inform your healthcare provider if you're unsure about how to proceed after a missed dose.
An overdose of Emgality (Galcanezumab) medicine is rare, as it is administered through monthly injections. However, taking more than the recommended Emgality dosage could increase the risk of adverse effects without improving effectiveness. Signs may include:
Seek medical help immediately if overdose symptoms occur. Always follow dosage instructions and never self-administer more than prescribed without consulting your doctor.
Consult your doctor before taking any medication. If you suspect an overdose, seek emergency medical help right away.
Get a second opinion from trusted experts and makeconfident, informed decisions.
Get Second OpinionGalcanezumab is generally well-tolerated, but some individuals may experience mild to moderate side effects, especially when starting the treatment. It's important to be aware of potential reactions and inform your doctor if symptoms become bothersome or persist. Most side effects do not require medical attention and fade as your body adjusts to the medicine.
Common side effects of Emgality include:
Serious reactions may include:
Before starting Emgality (Galcanezumab) medicine, inform your doctor about any existing conditions. It may not be suitable for:
Use caution if you're taking multiple migraine treatments or have other chronic health conditions. Always discuss any new symptoms, especially if you are adjusting the Emgality dosage or starting a new medication while on treatment.
Galcanezumab is approved for use in adults aged 18 years and older. Its safety and effectiveness in children or adolescents under 18 have not been fully studied. Older adults can use Emgality, but monitoring may be needed to check for tolerance, especially if they have multiple health conditions. Always consult a healthcare provider to determine if this treatment is suitable for you, taking into account your age and medical history.
Galcanezumab medicine does not have any known direct interactions with food or alcohol. However, alcohol is known to trigger migraines in some individuals, so it's best to limit or avoid it during treatment. Food has no effect on the effectiveness of Emgality. You can maintain your normal diet while taking this medication unless otherwise directed by your doctor based on other health conditions or treatments.
Galcanezumab medicine generally has a low risk of drug interactions due to its targeted mechanism. However, caution should be exercised if you are using:
Always provide your doctor with a full list of medicines and supplements before starting treatment. Combining treatments may alter how well Emgality works or increase side effect risks, especially with overlapping therapies.
Proper storage ensures the effectiveness of Emgality (Galcanezumab) medicine:
Do not use the medicine if it has changed colour or appears cloudy. Always keep it out of reach of children and dispose of expired or unused doses responsibly.
| Galcanezumab (Emgality) | Ajovy (Fremanezumab) |
|---|---|
| Used for migraine prevention | Used for migraine prevention |
| Administered as a monthly injection | Can be given monthly or quarterly |
| An initial loading dose is usually required | No loading dose required |
| FDA-approved for episodic and chronic migraine | FDA-approved for episodic and chronic migraine |
| Belongs to the CGRP monoclonal antibody class | Also, a CGRP monoclonal antibody |
| Common side effects: injection site pain, constipation | Common side effects: injection site reactions |
| Delivered via prefilled syringe | Available as a prefilled syringe or an autoinjector |
| Brand Name: Emgality | Brand Name: Ajovy |

Still have questions? Speak with our experts now!
040-68334455Yes, some people who take Emgality to prevent migraines or treat cluster headaches may gain weight.
When Emgality is used to treat cluster headaches, it begins to work within one week of beginning treatment, but it may take up to three weeks for the full effects to be seen.
If you are allergic to this medicine, you should not use Emgality. Emgality is not intended for use by anyone under the age of 18. If you are pregnant, notify your doctor. It is unknown whether it will harm a developing baby.
If your body develops antibodies to one of these drugs, the drug may no longer work for you. In clinical trials lasting up to a year, 12.5 percent of people taking 120 mg of Emgality per month developed antibodies to the drug.
Yes, Emgality injections can be painful. One of the most common side effects reported with Emgality injections is pain at the injection site, which occurs in 18% of people. Other injection site reactions are also common, such as redness, swelling, or itching around the injection site.
Emgality does not cause fatigue (lack of energy). Fatigue was not reported in the drug's studies. However, if you suffer from migraines on a regular basis, this may cause fatigue.
Emgality is a calcitonin-gene-related peptide antagonist, and Imitrex is a selective serotonin receptor agonist (a triptan). Injection site reactions are among the Emgality side effects that differ from Imitrex (such as pain, redness, and itching)
Yes, it can cause minor dizziness and drowsiness.
Inject galcanezumab subcutaneously in the thigh, abdomen, or upper arm using a prefilled pen, as directed by your doctor.
Disclaimer: The information provided is accurate and up-to-date to the best of our knowledge. However, it should not be considered a substitute for medical advice or consultation. We do not guarantee its completeness or accuracy. The absence of specific warnings does not mean a medicine is safe for all users. We are not responsible for any outcomes based on this information and strongly recommend consulting a doctor for any medical concerns or questions.